Play it again, Wilex
German cancer play Wilex AG has started a Phase III trial enrolling 540 breast cancer patients with high risk of developing metastases. But the study is not just one of thousands of cancer studies; indeed, Wilex is not even testing one of its compounds. Instead, the study will investigate the efficacy of Docetaxel, a taxotere developed by Aventis S.A.
The ADEBAR (Adjuvant Docetaxel vs. Epirubicin Based Regimen) trial will investigate the efficacy of Docetaxel in several combinations with anthracycline chemotherapy. At the same time, Wilex will collect clinical data, including gene expression profiles and marker protein concentrations, which could help it to select potential combination therapies for its own small molecule cancer compounds...